Evidence map›Paper›PMID 38806188›Full record

ArticleRMD open2024

Dysregulation of circulating collagen turnover markers in very early systemic sclerosis.

Rucsandra Dobrota, Suzana Jordan, Pernille Juhl, Nicoletta Del Papa, Britta Maurer, Mike Becker, Carina Mihai, Anne-C Bay-Jensen, Morten Asser Karsdal, Anne Sofie Siebuhr and 1 more

Abstract read
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rucsandra DobrotaDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-9819-7574
Suzana JordanDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Pernille JuhlBiomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Nicoletta Del PapaScleroderma Clinic, Department of Rheumatology, ASST G. Pini-CTO, Universita degli Studi di Milano, Milano, Italy.
Britta MaurerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Mike BeckerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Carina MihaiDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-8627-8817
Anne-C Bay-JensenDepartment of Immunoscience, Nordic Bioscience, Herlev, Denmark.
Morten Asser KarsdalDepartment of Immunoscience, Nordic Bioscience, Herlev, Denmark.
Anne Sofie SiebuhrDepartment of Immunoscience, Nordic Bioscience, Herlev, Denmark.
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland Oliver.Distler@usz.ch.ORCID 0000-0002-0546-8310

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveClinical observation suggests that vascular activation and autoimmunity precede remodelling of the extracellular matrix (ECM) in systemic sclerosis (SSc). We challenge this paradigm by hypothesising that ECM biomarkers are already disturbed in patients with very early SSc (veSSc) when fibrosis is not yet clinically detectable.

methods42 patients with veSSc, defined as the presence of Raynaud's phenomenon and at least one of puffy fingers, positive antinuclear antibodies or pathological nailfold capillaroscopy, not meeting the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for SSc, were compared with healthy controls (HCs, n=29). ECM degradation (BGM, C3M, C4M and C6M) and ECM formation biomarkers (PRO-C3, PRO-C4 and PRO-C5) were measured in serum using ELISAs. A cross-sectional analysis at baseline and a longitudinal analysis was performed.

resultsCompared with HC, veSSc patients showed a strongly dysregulated turnover of type III and IV collagens (higher C3M, C4M, both p<0.0001 and PRO-C3, p=0.004, lower turnover ratios PRO-C3/C3M and PRO-C4/C4M, both p<0.0001). The biglycan degradation biomarker BGM was higher in veSSc than in HC (p=0.006), whereas the degradation biomarker for type VI collagen, C6M, was lower (p=0.002). In an ROC analysis, biomarkers of type III and IV collagen excellently distinguished between veSSc and HC: C3M, AUC=0.95, p<0.0001; C4M, AUC=0.97, p<0.0001; turnover ratios PRO-C3/C3M, AUC=0.80, p<0.0001; PRO-C4/C4M, AUC=0.97; p<0.0001.

conclusionThese findings indicate ECM remodelling as a very early phenomenon of SSc occurring in parallel with microvascular and autoimmune changes. Biomarkers of type III and IV collagens distinguished between veSSc patients and HC, indicating them as potential biomarkers for the detection of veSSc.

Indexed as

BiomarkersScleroderma, SystemicAdultAgedBiglycanCase-Control StudiesCollagenCollagen Type IIICross-Sectional StudiesExtracellular MatrixFemaleHumansMaleMiddle AgedROC CurveBiglycanBiomarkersCollagenCollagen Type IIIautoimmune diseasescollagen type VIconnective tissue diseasessystemic sclerosis

Identifiers

PMID38806188
PMCPMC11138262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.